This Swedish Startup Just Raised $100M to Fix Europe's Healthcare AI Gap

Jan de Vries · 2026-09-14

### The $100 Million Bet on European Healthcare AI Tandem Health, a Stockholm-based healthtech startup, just closed a $100 million Series B round. That's a huge vote of confidence for a company building an AI-native operating system specifically for European clinics. The round was led by the Scaleup Europe Fund, managed by EQT, with existing investors Kinnevik, Northzone, Amino Collective, and Visionaries also participating. This follows a $49 million Series A in June 2025, bringing total funding to $160 million. So why are investors so excited? Because Tandem is solving a problem that's been nagging European healthcare for years: the lack of AI tools built for Europe's unique regulatory and clinical landscape. ### Why Europe Needs Its Own AI Healthcare Solution Lukas Saari, CEO and co-founder, put it bluntly: "Europe's health systems are under real strain and AI presents a real solution. But until now, European care providers have had to depend either on legacy solutions or AI solutions originally built for other markets that were retrofitted for Europe." He's got a point. Most AI medical tools are designed for the U.S. market, then awkwardly adapted for Europe. That's like trying to fit a square peg in a round hole—it might work, but it's never quite right. Tandem flips that script. They're building from the ground up for European healthcare, with all its complexities: multiple languages, varying regulations, and different care models. ### What Exactly Does Tandem Health Do? Tandem's AI medical assistant supports clinicians before, during, and after patient visits. Here's the breakdown: - **Before the visit:** It prepares patient summaries, so doctors walk in already knowing the key details. - **During the visit:** It provides clinical decision support, helping clinicians make informed choices in real time. - **After the visit:** It automatically handles documentation and coding, freeing up hours of admin work. And it's not just any AI. Tandem claims to be the only AI medical assistant with an AI scribe, coding assistant, and clinical decision support—each independently certified as a Class IIa medical device under EU regulations. They're also certified under ISO 27001, ISO 13485, ISO 42001, and various national standards like C5 in Germany and HDS in France. That's a lot of acronyms, but the takeaway is simple: this is regulatory-grade AI that clinicians can actually trust. ### The Real-World Impact: Less Admin, More Care Tandem cites peer-reviewed research showing that clinicians using their tool saw: - A 29% reduction in time spent on admin - A 30% improvement in job satisfaction - A 30% reduction in administrative stress That's not just numbers—it's a lifeline for overworked doctors and nurses. And with more than 10,000 care organizations already using Tandem across Europe, the impact is scaling fast. Nils Petter Nygaard, Managing Director at EQT and Scaleup Europe Fund, believes Tandem could become "the foundational AI layer for European healthcare over the coming decades." That's a bold claim, but the traction suggests it's not just hype. ### What's Next for Tandem Health? With this fresh capital, Tandem plans to double down across markets and expand its clinician-led team, which already includes over 75 in-house clinicians. They're also fresh off the acquisition of Dutch AI medical scribe Juvoly, which will help them scale clinician-first AI documentation across Europe. The Scaleup Europe Fund, targeting €5 billion ($5.4 billion), was initiated by the European Commission and is managed by EQT. It's designed to back ambitious European tech companies at scale, and Tandem is clearly a flagship bet. In a nutshell, Tandem Health is building the AI backbone for European healthcare—and investors are betting big that they'll succeed. If they do, it could mean better care, less burnout, and a more sustainable system for everyone.